High Dose Tamoxifen For Brain Tumors
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

Tamoxifen Reference List
Click HERE to go back to the Tamoxifen Paper

1.   Al-Nabulsi, I., R.H. Mach, L.M. Wang, C.A. Wallen, P.C. Keng, K. Sten, Childers, SR, and K.T. Wheeler.
  Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. British Journal of Cancer 81: 925-933, 1999.
2.   Allen, M.C., C. Newland, M.A. Valverde, and S.P. Hardy.
  Inhibition of ligand-gated cation-selective channels by tamoxifen. European Journal of Pharmacology 354: 261-269, 1998.
3.   Anonymous.
  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet351: 1451-1467, 1998.
4.   Assikis, V.J., P. Neven, V.C. Jordan, and I. Vergote.
  A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. [Review] [75 refs]. European Journal of Cancer 32A: 1464-1476, 1996.
5.   Baltuch, G.H., N.P. Dooley, J.G. Villemure, and V.W. Yong.
  Protein kinase C and growth regulation of malignant gliomas. [Review] [98 refs]. Canadian Journal of Neurological Sciences 22: 264-271, 1995.
6.   Baltuch, G.H., N.P. Dooley, K.M. Rostworowski, J.G. Villemure, and V.W. Yong.
  Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. Journal of Neuro-Oncology 24: 241-250, 1995.
7.   Baltuch, G.H. and V.W. Yong.
  Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Research 710: 143-149, 1996.
8.   Bedford, G.R. and D.N. Richardson.
  Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 212: 7331966.
9.   Ben, A.M., S. Postovsky, D. Goldsher, H.R. el, and S. Constantini.
  . Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen. Pediatric Hematology & Oncology 16: 245-250, 1999.
10.   Bergan, R.C., E. Reed, C.E. Myers, D. Headlee, O. Brawley, H.K. Cho, W.D. Figg, A. Tompkins, W.M. Linehan, D. Kohler, S.M. Steinberg, and M.V. Blagosklonny.
  . A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clinical Cancer Research 5: 2366-2373, 1999.
11.   Brandes, A.A., M. Ermani, S. Turazzi, E. Scelzi, F. Berti, P. Amista, Rotilio, C. Licata, and M.V. Fiorentino.
  Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. Journal of Clinical Oncology 17: 645-650, 1999.
12.   Bredel, M. and I.F. Pollack.
  The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. [Review] [188 refs]. Acta Neurochirurgica 139: 1000-1013, 1997.
13.   Broniscer, A., C.C. Leite, V.L. Lanchote, T.M. Machado, and L.M. Cristofani.
  . Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. Journal of Clinical Oncology 18: 1246-1253, 2000.
14.   Carlson, R.W.
  . Scientific review of tamoxifen. Overview from a medical oncologist. [Review] [19 refs]. Seminars in Oncology 24: S1-S11997.
15.   Chamberlain, M.C. and P.A. Kormanik.
  Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Archives of Neurology 56: 703-708, 1999.
16.   Chang, J.C.
  A review of breast cancer chemoprevention. [Review] [19 refs]. Biomedicine & Pharmacotherapy 52: 133-136, 1998.
17.   Chang, S.M., F.G. Barker, S.L. Huhn, M.K. Nicholas, M. Page, J. Rabbitt, and M.D. Prados.
  High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. Journal of Neuro-Oncology 37: 169-176, 1998.
18.   Cho, K.K., T. Mikkelsen, Y.J. Lee, F. Jiang, M. Chopp, and M.L. Rosenblum.
  The role of protein kinase C alpha in U-87 glioma invasion. International Journal of Developmental Neuroscience 17: 447-461, 1999.
19.   Cloughesy, T.F., R.P. Woods, K.L. Black, W.T. Couldwell, R.E. Law, and D.R. Hinton.
  Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. Journal of Neuro-Oncology 35: 39-45, 1997.
20.   Cokgor, I., H.S. Friedman, and A.H. Friedman.
  Chemotherapy for adults with malignant glioma. [Review] [92 refs]. Cancer Investigation 17: 264-272, 1999.
21.   Couldwell, W.T., M.H. Weiss, C.M. DeGiorgio, L.P. Weiner, D.R. Hinton, Ehresmann, GR, P.S. Conti, and M.L. Apuzzo.
  . Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-489, 1993.
22.   Couldwell, W.T., M.H. Weiss, R.E. Law, and D.R. Hinton.
  Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas. Journal of Neurosurgery 82: 461-468, 1995.
23.   Couldwell, W.T., D.R. Hinton, A.A. Surnock, C.M. DeGiorgio, L.P. Weiner , M.L. Apuzzo, L. Masri, R.E. Law, and M.H. Weiss.
  . Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical Cancer Research 2: 619-622, 1996.
24.   Damek, D.M. and F.H. Hochberg.
  Clinical aspects of brain tumor. [Review] [49 refs]. Current Opinion in Neurology 10: 452-458, 1997.
25.   daMotta LA and daMotta LD.
  . [Endocrine treatment of meningiomas: a review]. [Review] [45 refs] [Portuguese]. Arquivos de Neuro-Psiquiatria 53: 324-332, 1995.
26.   daRocha AB, D.R. Mans, E.A. Bernard, C. Ruschel, A.F. Logullo, L.A. Wetmore, A. Leyva, and G. Schwartsmann.
  Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. European Journal of Cancer 35: 833-839, 1999.
27.   DeMattia, J.A., W. Zhang, and W.T. Couldwell.
  . Tyrosine kinase inhibitors - potential for the treatment of primary brain tumours. CNS DRUGS 12: 421-430, 1999.
28.   Donson, A.M., M.D. Weil, and N.K. Foreman.
  Tamoxifen radiosensitization in human glioblastoma cell lines. Journal of Neurosurgery 90: 533-536, 1999.
29.   Ducharme, J., K. Fried, G. Shenouda, B. Leyland-Jones, and I.W. Wainer.
  Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. British Journal of Clinical Pharmacology 43: 189-193, 1997.
30.   Flaherty, L.E., P.Y. Liu, M.S. Mitchell, W.S. Fletcher, Walker, MJ, J.W. Goodwin, R.L. Stephens, and V.K. Sondak.
  The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). American Journal of Clinical Oncology 19: 108-113, 1996.
31.   Fraser, C.L. and R.A. Swanson.
  Female sex hormones inhibit volume regulation in rat brain astrocyte culture. American Journal of Physiology 267: C909-C9141994.
32.   Gattis, W.A. and D.B. May.
  Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. [Review] [20 refs]. Annals of Pharmacotherapy 30: 520-526, 1996.
33.   Gradishar, W.J. and V.C. Jordan.
  Clinical potential of new antiestrogens. [Review] [138 refs]. Journal of Clinical Oncology 15: 840-852, 1997.
34.   Greenberg, H.S.
  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin - corroborating clinical response in vitro: Case report:Comment. Neurosurgery 38: 5911996.
35.   Hahnel, R. and M. Gschwendt.
  The interaction between protein kinase C (PKC) and estrogens (Review). International Journal of Oncology 7: 11-16, 1995.
36.   Haux, J.
  Digitoxin is a potential anticancer agent for several types of cancer. [Review] [50 refs]. Medical Hypotheses 53: 543-548, 1999.
37.   Huncharek, M. and J. Muscat.
  Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Research 18: 1303-1311, 1998.
38.   Ikemoto, H., E. Tani, T. Matsumoto, A. Nakano, and J. Furuyama.
  Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. Journal of Neurosurgery 83: 1008-1016, 1995.
39.   Iwasaki, K., S.A. Toms, G.H. Barnett, M.L. Estes, M.K. Gupta, and B.P. Barna.
  Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells. Cancer Immunology, Immunotherapy 40: 228-234, 1995.
40.   Kellen, J.A.
  Genomic effects of tamoxifen. [Review] [52 refs]. Anticancer Research 16: 3537-3541, 1996.
41.   Kuiper, G.G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J.A. Gustafsson.
  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870, 1997.
42.   Lee, Y.S. and R.D. Wurster.
  . Bepridil enhances in vitro antitumor activity of antiestrogens in human brain tumor cells. Cancer Letters 110: 243-248, 1996.
43.   Leslie, K.K., D. Keefe, S. Powell, and F. Naftolin.
  Estrogen receptors are identified in the glioblastoma cell line U138MG. Journal of the Society for Gynecologic Investigation 1: 238-244, 1994.
44.   Lesser, G.J.
  Chemotherapy of cerebral metastases from solid tumors. [Review] [73 refs]. Neurosurgery Clinics of North America 7: 527-536, 1996.
45.   Lifshits, A.L.
  [Special features in the clinical aspects of brain tumors in children]. [Russian]. Meditsinskaia Sestra 32: 19-21, 1973.
46.   Lippmann, M.E. and G. Bolan.
  . Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256: 592-593, 1975.
47.   Luo, W., T.R. Sharif, P.J. Houghton, and M. Sharif.
  CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth & Differentiation 8: 1225-1240, 1997.
48.   Mastronardi, L., J.O. Farah, F. Puzzilli, and A. Ruggeri.
  Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line. Clinical Neurology & Neurosurgery 100: 89-93, 1998.
49.   Mastronardi, L., F. Puzzilli, W.T. Couldwell, J.O. Farah, and P. Lunardi .
  Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. Journal of Neuro-Oncology 38: 59-68, 1998.
50.   Mastronardi, L., F. Puzzilli, and A. Guiducci.
  Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy [letter; comment]. Neurosurgery 43: 14961998.
51.   Mastronardi, L., F. Puzzilli, and A. Ruggeri.
  Tamoxifen as a potential treatment of glioma. [Review] [65 refs]. Anti-Cancer Drugs 9: 581-586, 1998.
52.   Musella, A.
  Virtual Trials for Brain Tumors. Ongoing Study. http://www.virtualtrials.com 2000
53.   Nieder, C., K. Walter, U. Nestle, and K. Schnabel.
  Ten years disease-free survival after solitary brain metastasis from breast cancer. Journal of Cancer Research & Clinical Oncology 122: 570-572, 1996.
54.   Peto, R., J. Boreham, M. Clarke, C. Davies, and V. Beral.
  UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 18222000.
55.   Piepmeier, J.M.
  . Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: Corroborating clinical response in vitro:Case report- Comment. Neurosurgery 38: 590-591, 2000.
56.   Pollack, I.F. and S. Kawecki.
  The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatric Neurosurgery 22: 281-288, 1995.
57.   Pollack, I.F., S. Kawecki, and J.S. Lazo.
  Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. Journal of Neurosurgery 84: 1024-1032, 1996.
58.   Pollack, I.F., R.C. DaRosso, P.L. Robertson, R.L. Jakacki, J.R.J. Mirro, J. Blatt, S. Nicholson, R.J. Packer, J.C. Allen , A. Cisneros, and V.C. Jordan.
  A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clinical Cancer Research 3: 1109-1115, 1997.
59.   Pollack, I.F. and S. Kawecki.
  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. Journal of Neuro-Oncology 31: 255-266, 1997.
60.   Pollack, I.F., M. Bredel, and M. Erff.
  Application of signal transduction inhibition as a therapeutic startegy for central nervous system tumors. Pediatric Neurosurgery 29: 228-244, 1998.
61.   Powles, T., R. Eeles, S. Ashley, D. Easton, J. Chang, M. Dowsett, A. Tidy, J. Viggers, and J. Davey.
  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments]. Lancet 352: 98-101, 1998.
62.   Preul, M.C., Z. Caramanos, J.G. Villemure, G. Shenouda, R. LeBlanc, A. Langleben, and D.L. Arnold.
  Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46: 306-318, 2000.
63.   Pritchard, K.I.
  Is tamoxifen effective in prevention of breast cancer? [comment] [see comments]. Lancet 352: 80-81, 1998.
64.   Rabinowicz, A.L., D.R. Hinton, P. Dyck, and W.T. Couldwell.
  High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 36: 513-515, 1995.
65.   Richard, M.A., J.J. Grob, H. Zarrour, N. Basseres, J.P. Bizzari, B. Gerard, and J.J. Bonerandi.
  Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Research 8: 170-174, 1998.
66.   Rostagno, P., J.L. Moll, I. Birtwisle-Peyrottes, F. Ettore, J.L. Lagrange, J. Gioanni, and C. Caldani.
  Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling. Anticancer Research 14: 2025-2032, 1994.
67.   Sasco, A.J., R. Ah-Song, S. Saez, and F. Kuttenn.
  . [Medical adverse effects of chemoprevention: the example of tamoxifen]. [Review] [116 refs] [French]. Bulletin du Cancer 82 Suppl 3: 186s-206s, 1995.
68.   Sharif, M.
  Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines (review). International Journal of Oncology 12: 273-286, 1998.
69.   Sharif, T.R. and M. Sharif.
  A novel approach for examining the anti-proliferative effect of protein kinase C inhibitors against human astrocytoma cells. International Journal of Oncology 13: 685-692, 1998.
70.   Sharif, T.R. and M. Sharif.
  A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells. International Journal of Oncology 14: 327-335, 1999.
71.   Shlebak, A.A. and D.B. Smith.
  Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemotherapy & Pharmacology 39: 462-466, 1997.
72.   Shy, H., L. Malaiyandi, and P.S. Timiras.
  Protective action of 17 beta-estradiol and tamoxifen on glutamate toxicity in glial cells. International Journal of Developmental Neuroscience 18: 289-297, 2000.
73.   Simonetti, R.G., A. Liberati, C. Angiolini, and L. Pagliaro.
  Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. [Review] [54 refs]. Annals of Oncology 8: 117-136, 1997.
74.   Soroceanu, L., T.J.J. Manning, and H. Sontheimer.
  Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. Journal of Neuroscience 19: 5942-5954, 1999.
75.   Stearns, V. and E.P. Gelmann.
  Does tamoxifen cause cancer in humans? [see comments]. [Review] [143 refs]. Journal of Clinical Oncology 16: 779-792, 1998.
76.   Toms, S.A., A. Hercbergs, J. Liu, S. Kondo, T. Haqqi, G. Casey, K. Iwasaki, G.H. Barnett, and B.P. Barna.
  Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. Journal of Neurosurgery 88: 884-889, 1998.
77.   Uhm, J.H., N.P. Dooley, J.G. Villemure, and V.W. Yong.
  Mechanisms of glioma invasion: role of matrix-metalloproteinases. [Review] [143 refs]. Canadian Journal of Neurological Sciences 24: 3-15, 1997.
78.   vanRijswijk RE, O.R. van, and A. Twijnstra.
  A case of brain metastases from male breast cancer responding to tamoxifen [letter]. European Journal of Cancer 33: 2282-2283, 1997.
79.   Veronesi, U., P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, and P. Boyle.
  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study [see comments]. Lancet 352: 93-97, 1998.
80.   Weller, M., M. Trepel, C. Grimmel, M. Schabet, D. Bremen, S. Krajewski, Reed, and JC.
  Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurological Research 19: 459-470, 1997.
81.   Williams, C.J.
  Tamoxifen in relapsed ovarian cancer: A systematic review. International Journal of Gynecological Cancer 8: 89-94, 1998.
82.   Wogan, G.N.
  Review of the toxicology of tamoxifen. [Review] [36 refs]. Seminars in Oncology 24: S1-S11997.
83.   Wolf, D.M. and S.A. Fuqua.
  Mechanisms of action of antiestrogens. [Review] [175 refs]. Cancer Treatment Reviews 21: 247-271, 1995.
84.   Zeltzer, P.M., B. Moilanen, J.S. Yu, and K.L. Black.
  Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. [Review] [84 refs]. Childs Nervous System 15: 514-528, 1999.
85.   Zhang, W., D.R. Hinton, A.A. Surnock, and W.T. Couldwell.
  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 38: 587-590, 1996.
86.   Zhang, W., R.E. Law, D.R. Hinton, and W.T. Couldwell.
  Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Letters 120: 31-38, 1997.

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557